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Abstract
Activating mutations in Ras (N- and K-) are the most common point mutations found in patients with multiple myeloma
(MM) and are associated with poor clinical outcome. We sought to directly examine the role of Ras activation in MM
pathogenesis and used two different tissue-specific Cre recombinase mouse lines (Cc1-Cre and AID-Cre), to generate mice
with mutant Kras (KrasG12D) activated specifically in germinal center B-cells. We also generated mice with activation of the
KrasG12D allele in a tumor-prone Arf-null genetic background. Surprisingly, we observed no significant disruption in B-cell
homeostasis in any of these models by serum immunoglobulin ELISA, SPEP, flow cytometry and histological examination.
We observed development of non-overlapping tumor types due to off-target Cre expression, but despite successful
recombination in germinal center and later B-cell populations, we observed no B-cell phenotype. Together, these data
demonstrate that Ras activation is not sufficient to transform primary germinal center B-cells, even in an Arf-null context,
and that the temporal order of mutation acquisition may be critical for myeloma development. Specific pathways, yet to be
identified, are required before Kras can contribute to the development of MM.
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Introduction
Multiple myeloma (MM) is an incurable malignancy of
antibody-secreting plasma B-cells, whose etiology remains poorly
understood. Mutations in Ras genes, encoding key proteins
regulating cell growth, differentiation and survival, occur com-
monly in MM with a prevalence of 20–39% [1–3]. Indeed, using a
targeted sequencing approach to screen highly expressed tyrosine
kinase and cytokine signaling genes in primary human patient
myeloma, we previously identified mutations at codon 12 and 61
in N- and KRAS as being the only recurrent variation in our
sample set [4]. Recent genome sequencing efforts also found Ras
mutations to be the most common single nucleotide variant (SNV)
in MM [4], suggesting that Ras activation is an important event in
MM pathogenesis. The somatic SNVs found most frequently in
MM are gain-of-function mutations in Ras oncogenes (Kras and
Nras), causing constitutive activation of the Ras protein [5].
Despite the genomic evidence for Ras pathogenesis, the
functional role of Ras activation in MM has not previously been
tested. This issue is not trivial as the induction of neoplasia by Ras
activation is highly dependent on cellular context [6]. Under-
standing the effects of Ras activation in mature B-cells will allow us
to better define the downstream pathways critical for development
of MM. Moreoever, pharmaceutical approaches to target cancers
with mutant Ras are underway [7–10], and a pre-clinical model
faithfully replicating Ras-driven myeloma would be critical in
evaluating the therapeutic potential of these agents in myeloma.
Post-germinal center (GC) B-cells are strongly implicated as the
cell of origin in MM by demonstration of stable immunoglobulin
(Ig) switch clonotypes over the course of disease [11,12]. To test if
expression of oncogenic Ras in GC B-cells was sufficient to induce
myeloma, we utilized transgenic mice harboring a constitutively
active Kras (G12D mutation) knocked-in to the endogenous Kras
locus and flanked by a Lox-Stop-Lox cassette [13]. The Kras
mouse model has been successfully used in several labs in
developing cancer models [14,15] [13,16]. These mice were
crossed with two different mature B cell-specific Cre recombinase
(Cre) mouse strains (Cc1-Cre and AID-Cre) to definitively test the
effects of Ras activation in post-GC B-cells, including downstream
memory B and plasma cells [17,18]. As Ras activation can induce
cellular senescence [19] and often requires cooperating mutations
to induce transformation, so we also generated a strain of triple
transgenic mice by crossing KrasG12D mice with mice null for the
P19ARF tumor-suppressor gene (Arf 2/2) [20]. Arf (P14ARF in
humans) is a potent tumor suppressor gene that cooperates with
Ras activation in cellular transformation and carcinogenesis
[21,22]. In patients with myeloma, the P14/P16 locus is
methylated in 42% [23], although the biological significance of
this epigenetic modification is contested [24].
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Surprisingly, in these settings we found B-cell development to be
only subtly perturbed, even in the setting of Arf deficiency.
Conversely, mice frequently developed tumors harboring Cre-
recombined Ras alleles in non-B-cell tissues due to small amounts
of off-target Cre expression. These data demonstrate that post-GC
B-cells are resistant to transformation by mutations that are
strongly oncogenic in other cellular contexts and that Ras
activation must likely cooperate with tissue-specific mutations or
epigenetic events to induce myeloma.
Results
Cc1-Cre KrasG12D Mice Develop Thymic Lymphomas and
Lung Adenomas but not Myeloma
To examine the effect of Kras in plasma cells, we generated
double transgenic mice. In KrasG12D mice, the G12D mutation is
knocked-in to the endogenous Kras locus, upstream of the Lox-
Stop-Lox cassette (Figure 1A,B). KrasG12D mice were crossed with
mice expressing Cre recombinase (Cre) under control of the Ig
heavy chain locus (Cc1-Cre) reported to express Cre selectively in a
subset of germinal center B-cells (Figure 1C).
We first confirmed that wild type Kras is strongly expressed in
murine B-lineage cells; naı¨ve splenic B-cells, germinal center B-
cells, memory B-cells and plasma cells from C57BL/6 mice
(Figure 2A) [25]. As expected, Cre-mediated excision of the Kras
allele stop cassette was robust and specific to B-lineage cells
undergoing class-switch recombination in vitro (Figure 2B and
Figure S1). We also confirmed Cre-recombination in vivo in
mature B-cell populations isolated from Cc1-Cre KrasG12D mice by
fluorescence associated cell sorting (FACS). Splenic germinal
center B-cells (B220+/IgM2/GL7+) and class switched memory/
plasma cells (IgG1+) demonstrated clear, albeit low-level recom-
bination, as did bone marrow plasma cells (B220lo/CD138+,
Figure 2C).
We aged Cc1-Cre KrasG12D mice, both naı¨ve and immunized
with chicken gamma globulin to expand plasma cells, to
monitor the development of disease. After 100 days, 58%
(n = 12) of naı¨ve mice developed weight loss, ruffled fur and
shortness of breath and were found on necropsy to have
thoracic cavity tumors. Unexpectedly, these tumors were T-
lymphoblastic in phenotype (CD4+CD8+) by flow cytometry
(Figure S2A). Additionally, 42% (n = 12) of naı¨ve Cc1-Cre
KrasG12D mice and 66% (n = 7) CGG-immunized Cc1-Cre
KrasG12D mice were found to have lung nodules at autopsy
(300 day endpoint). Sections of lung from immunized Cc1-Cre
KrasG12D show well-demarcated nodules composed mostly of
sheets of bronchial epithelial cells and some ‘‘signet ring’’ cells
with bland nuclear features and absence of mitotic figures
consistent with adenomas or low-grade adenocarcinomas (Fig-
ure S2B–E). Tissue from lung tumors in two independent Cc1-
Cre KrasG12D mice shows partial recombination of the Kras allele
(Figure S2F). The immunized and unimmunized negative
control Cc1-Cre mice showed no evidence of disease
(Figure 3A). Tissue from T-cell lymphomas found in two
separate unimmunized Cc1-Cre KrasG12D mice showed complete
Kras allele recombination, suggestive of loss of the wild-type
allele, whereas spleen showed a partial recombination pattern
consistent with infiltration of the spleen with these same cells
(Figure 3B). Despite extensive analysis, no B-lineage oncogenic
transformation was observed in any Cc1-Cre KrasG12D mice. B-
cell subsets in spleen and bone marrow and serum immuno-
globulin levels were all normal (data not shown). Taken
together, these data suggest that KrasG12D allele activation in
germinal center B-cells failed to perturb B-cell homeostasis in
Cc1-Cre KrasG12D mice.
AID-Cre-YFP KrasG12D Mice Develop Focal Epidermal
Papillomas
Noting the low level of in vivo recombination in Cc1-Cre
KrasG12D mice (Figure 2C), and the lack of appreciable B- or
plasma cell phenotype, we generated a second strain of mice
using an independent tissue specific Cre allele. We crossed the
KrasG12D mice with mice expressing Cre recombinase under the
control of the activation-induced cytosine deaminase (AID) gene
(Figure 1D). AID is expressed with exquisite specificity in B-
cells undergoing the germinal center reaction where it mediates
class switch recombination and somatic hypermutation. To
facilitate our analysis, this strain of mice also included the
Rosa26-EYFP reporter allele, which allowed us to effectively
track B-cells where recombination had occurred (AID-Cre-YFP
KrasG12D). Upon cre-mediated recombination, YFP marks cells
where KrasG12D is also expressed. In an attempt to stimulate
malignant B-cell transformation in AID-Cre-YFP KrasG12D mice,
vitamin D deficient chow and/or sub-lethal radiation was given
to cohorts of mice after immunization.
Robust KrasG12D allele recombination was induced in AID-Cre-
YFP KrasG12D splenic B-cells undergoing plasmacytic differentia-
tion and class switch recombination ex vivo (Figure 4A). In
contrast to the weak levels of in vivo recombination observed in
Cc1-Cre KrasG12D mice, germinal center splenocyte populations and
post germinal center cells isolated from AID-Cre-YFP KrasG12D mice
showed robust Cre-mediated recombination at both the KrasG12D
locus (Figure 4B) and the YFP reporter in the spleen and to lesser
extent in the bone marrow (Figure 4C).
At 3 weeks of age, 100% (n = 20) AID-Cre-YFP KrasG12D mice
lacked fur on the ventral neck and developed small growths,
compared to control mice (Figure 5A,B). Radiation and
Vitamin D deficient chow (RV) treatments increased the
number and size of growths on AID-Cre-YFP KrasG12D mice as
early as 17 weeks, compared to AID-Cre-YFP KrasG12D given
neither (Figure 5C,D). By 26 weeks of age, all AID-Cre-YFP
KrasG12D mice receiving both irradiation and vitamin D deficient
chow (100%, n = 5) were hunched with ruffled fur and had
infected lesions over the cutaneous growths with a median
Figure 1. Schematic of alleles used in generating transgenic
mice. A) Floxed Kras allele with exons 0, 1, and 2, under the
endogenous Kras locus. Asterisk represents G12D mutation in exon 1.
B) Excision of the stop cassette of the Kras allele by Cre recombinase
allows the G12D mutation to activate. C) The Cre-coding sequence is
knocked in downstream of the last coding exon of the Cc1 locus.
Expression of Cre recombinase is induced by transcription of the Ig c1
constant region. D) After the floxed neomycin gene is deleted by Cre-
mediation, the YFP is expressed alongside AID-expressing B cells.
doi:10.1371/journal.pone.0067941.g001
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survival of 196 days (Figure 5E, F). AID-Cre-YFP KrasG12D
mice with no treatment (besides immunization) at 26 weeks had
an increase in the number of growths similar in appearance to
that at 17 weeks. At 17 weeks, KrasG12D mice given both
irradiation and vitamin D deficient chow appeared healthy
without growths, similar to the 26 week timepoint (data not
shown). All AID-Cre-YFP KrasG12D mice regardless of irradiation
or vitamin deficient chow subsequently died or were sacrificed
due to persistent skin infections associated with fungating skin
lesions (Figure 6A). The cutaneous lesions were identified by
histological examination to be benign papillomas (data not
shown). Papillomas from 3 separate AID-Cre-YFP KrasG12D mice
showed strong Cre-mediated recombination by PCR
(Figure 6B). A small increase in total serum gamma region
protein level achieved statistical significance in AID-Cre-YFP
KrasG12D mice fed vitamin deficient chow (Figure S3A, middle
panel), however the increase was not maintained over time, and
mice treated with radiation, or no treatment at all had no
significant changes in total serum gamma protein levels at any
time point (Figure S3A). Serum ELISA showed small changes
among the antibody subtypes in AID-Cre-YFP KrasG12D mice, but
no evidence of plasma cell transformation or any B-cell
malignancy was found (Figure S3B and data not shown).
Figure 2. Kras expression in B-cell subsets and tissue-specific recombination in Cc1-Cre KrasG12D mice. A) Expression of Ras genes by
microarray in primary mature B-cell subsets; naı¨ve splenic B-cells, germinal center B-cells, memory B-cells, and plasma cells. B) Successful Lox-Stop-
Lox excision from Kras locus in B cells of Cc1-Cre KrasG12D mice following class switch recombination. PCR of KrasG12D allele in B-cells of Cc1-Cre
KrasG12D mice stimulated to undergo class switch recombination ex vivo. Naı¨ve splenic B-cells were stimulated to undergo class switch recombination
with lipopolysaccharide (LPS) alone or LPS plus interleukin-4 (IL-4). Successful recombination was observed upon switch to IgG1 induced by LPS plus
IL-4. C) Fluorescence activated cell sorting (FACS) isolation of mature B-cell subsets directly from Cc1-Cre KrasG12D mice. In the first panel, bone
marrow mononuclear cells; second and third panels, splenic mononuclear cells, both panels gated for B220+. Red arrows indicate lanes with
detectable recombination. Recombination was low but detectable in bone marrow plasma cells (CD138+/B220low, lane 1); germinal center B-cells
(B220+/GL7+/IgMlow, lane 5) and IgG1 class switched splenic B-cells (B220+/IgM2/IgG1+, lane 9).
doi:10.1371/journal.pone.0067941.g002
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AID-Cre-YFP KrasG12D Arf2/2 Mice Develop Fatal
Epidermal Papillomas and Derivative Carcinomas
We reasoned that a lack of a detectable B-cell phenotype in Cc1-
Cre KrasG12D and AID-Cre-YFP KrasG12D mice was most likely due to
a requirement for a cooperating ‘‘second hit’’ to induce cellular
transformation. Therefore, to test the effects of a second mutation
known to cooperate with KrasG12D, we crossed AID-Cre-YFP
KrasG12D mice into a tumor-prone Arf-null background (Arf 2/2)
(Figure 1). All AID-Cre-YFP KrasG12D Arf 2/2 mice developed
rapidly progressive papillomas and by 13 wks, 66% of AID-Cre-
YFP KrasG12D Arf 2/2 mice (n = 3) developed cutaneous sarcomas
(Figure 7A), while AID-Cre-YFP Arf 2/2 control mice remained
disease-free (Figure 7B). Histopathological sections of spleen
from control mice show typical red pulp, white pulp and germinal
center structures (Figure 7D); whereas AID-Cre-YFP KrasG12D Arf
2/2 spleen showed defacement of splenic architecture with loss of
distinction between red and white pulp and a paucity of germinal
centers (Figure 7C). Sections of sarcomas from AID-Cre-YFP
KrasG12D Arf 2/2 showed characteristic undifferentiated spindle
cells (Figure 7E), consistent with tumors previously described in
Arf-deficient mice (10). The only abnormalities attributable to B-
cells that we identified were small but significant increases in
polyclonal antibody responses over time. The gamma protein
fraction by SPEP was higher in AID-Cre-YFP KrasG12D Arf 2/2 at
12 weeks compared to AID-Cre-YFP Arf 2/2 controls (Figure
S4C), but none of the mice developed multiple myeloma or
monoclonal gammopathy. AID-Cre-YFP KrasG12D Arf 2/2 and AID-
Cre-YFP KrasG12D Arf +/2 mice also showed significant differences
in total serum gamma region protein levels between baseline and
12 weeks (Figure S4A). Serum ELISA of antibody subtypes from
AID-Cre-YFP KrasG12D Arf 2/2, AID-Cre-YFP KrasG12D Arf +/2, and
control AID-Cre-YFP Arf 2/2 also showed small but significant
changes between baseline and 12 weeks in IgM and IgG
isosubtypes (Figure S4B), perhaps related to infected, fungating
papillomas in these mice. Flow cytometric immunophenotyping of
bone marrow and splenic mononuclear cells failed to detect the
abnormal growth in any B-cell populations in AID-Cre-YFP
KrasG12D Arf 2/2 mice.
Discussion
Kras is the oncogene most frequently mutated in MM, yet its role
in the pathogenesis of the disease has yet to be elucidated. Here,
we used a mouse model of activated Kras to directly test the effect
of activated Kras in post-germinal center B-cells using two
different Cre recombinases reported to be specific to germinal
center B-cells. These mice developed T-cell lymphomas, lung
Figure 3. Development of T-cell lymphomas in Cc1-Cre KrasG12D mice. A) Kaplan-Meier survival curves of aged Cc1-Cre KrasG12D mice and Cc1-
Cre control mice cohorts. Naı¨ve (unimmunized) Cc1-Cre KrasG12D mice (n = 12) developed fatal T-cell lymphomas with a median latency of 125 days.
Lung tumors were found incidentally at autopsy in both immunized Cc1-Cre KrasG12D (n = 7) and naı¨ve Cc1-Cre KrasG12D mice, while naı¨ve and
immunized Cc1-Cre were healthy for the duration and had no lung adenomas at autopsy. B) PCR detection of KrasG12D allele recombination in naı¨ve
Cc1-Cre KrasG12D mice with T-cell lymphomas. Recombination is detectable in unfractionated mononuclear splenic cells, consistent with infiltration of
spleen by lymphoma cells. Recombination with loss of wild-type allele observed in unfractionated cells isolated from thymic tumor tissue. Results
from two affected mice are shown.
doi:10.1371/journal.pone.0067941.g003
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adenomas, and sarcomas but no plasma cell tumors despite
evidence of activated Kras in vivo B-lineage cells. The Kras allele
was recombined in T-cell lymphomas and lung tumors, suggesting
these tumors developed as a consequence of off-target Cre
expression. In fact, T-cell lymphomas and lung adenomas have
been described in KrasG12D mice with Cre expressed via adenovirus
and Mx-1 respectively [14,15,26].
For malignant transformation in many contexts, activated Ras
requires cooperation with additional mutations [27] and we tried
several strategies to accelerate disease in AID-Cre-YFP KrasG12D
mice. Cohorts of AID-Cre-YFP KrasG12D mice were subjected to
vitamin D deficient chow or sub-lethal radiation or both in an
attempt to generate additional mutations and increase the
proliferation of pre-malignant B-cells. The combination of vitamin
D deficiency and radiation significantly accelerated and worsened
the development of skin tumors in AID-Cre-YFP KrasG12D mice, but
we observed no B-cell phenotype in any of these mice, despite
extensive analysis.
Lastly, we engineered mice with a specific cooperating
mutation, germinal center expression of KrasG12D in an Arf-null
background. The Ink4a gene locus encoding both Ink4a and Arf is
frequently silenced by hypermethylation in MM [28–30] and
mutated in some cases of MM ([31] and COSMIC database).
Germline mutations in INK4a affect predisposition to plasmacy-
tomas in mice [32] and to MM in people [33].
We observed significant acceleration of skin tumors and
progression to invasive carcinomas, demonstrating the successful
cooperation between the Kras and Arf pathways, but again, these
mice failed to demonstrate a significant B-cell phenotype. The
development of non-overlapping off-target tumors demonstrates
that KrasG12D can mediate oncogenicity, but germinal center B-
cells seem to possess an inherent resistance to its oncogenic effects.
Figure 4. Efficient tissue specific recombination of Kras in class switched B cells of AID-Cre-YFP KrasG12D mice. A) PCR of KrasG12D allele in
B-cells of AID-Cre-YFP KrasG12D mice stimulated to undergo class switch recombination ex vivo. Splenic B-cells were stimulated to undergo class switch
recombination with lipopolysaccharide (LPS) alone or LPS plus interleukin-4 (IL-4). In contrast to Cc1-Cre KrasG12D mice in Figure 2B, recombination
was seen following stimulation with LPS+IL-4 or with LPS alone. B) FACS-purification of mature B-cell subsets from AID-Cre-YFP KrasG12D mice and
detection of recombination by PCR. High-levels of Cre-mediated recombination in B220lo/CD138+ bone marrow plasma cells (lane 1), B220+/IgM2/
GL7+ splenic germinal center B-cells (lane 5) and B220+/IgM2/IgG1+ class switched memory B-cell populations (lane 9) in AID-Cre-YFP KrasG12D mice.
C) Detection of Cre-activated YFP reporter in cells isolated from spleen and bone marrow of AID-Cre-YFP KrasG12D mice given radiation and vitamin D
deficient chow. Recombined, YFP-positive cells are plentiful in spleen (6.4%) but rare in the bone marrow (0.20%). Experiment was repeated with
three mice and a representative example is shown.
doi:10.1371/journal.pone.0067941.g004
GC B-Cells Resist Transformation by Kras
PLOS ONE | www.plosone.org 5 June 2013 | Volume 8 | Issue 6 | e67941
We conclude that activation of Kras alone or in the context of Arf
pathway inactivation is insufficient to disrupt B-cell homeostasis.
These negative data demonstrate that GC B-cells are refractory to
mutations which are sufficient to transform other murine tissues,
and suggest that distinct tumor suppressor pathways may be active
in post-GC B-cells.
The temporal order of acquisition of mutations is likely to be
important in the development of some cancers. Observational
Figure 5. Gross appearance of cutaneous papillomas in AID-Cre-YFP KrasG12D mice is enhanced by tumor-promoting treatments. A) By
3 weeks of age, AID-Cre-YFP KrasG12D mice uniformly have hair loss and a single papilloma localized to the ventral neck; B) control KrasG12D mouse
shows normal hair pattern and no papilloma; C) By 17 weeks, AID-Cre-YFP KrasG12D mice given radiation and vitamin D deficient chow (RV) had
numerous fungating papillomas and more hair loss at the same site on the ventral neck; D) AID-Cre-YFP KrasG12D mice without tumor-promoting
treatments also had progressive papillomas but much fewer and with less hair loss associated; E) AID-Cre-YFP KrasG12D+RV mice aged to 26 weeks
showed confluent fungating and ulcerated masses at the ventral neck with spread to paws; F) age-matched control KrasG12D+RV mouse shows no
similar signs.
doi:10.1371/journal.pone.0067941.g005
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studies have suggested that Ras activation is a ‘‘late event’’ in
myeloma pathogenesis [34]. Ras mutations are significantly less
common in patients with monoclonal gammopathy of uncertain
significance (MGUS), and are not found in the memory B-cell
population of patients with MM, [34] and our data directly
supports the model that the temporal order of these events is
important to the development of myeloma disease. The lack of a
significant B-cell phenotype in our mice is reminiscent of the
intrinsic resistance to the effects of KrasG12D displayed by
intestinal cells. Intestinal homeostasis is unperturbed in mice by
expression of KrasG12D alone [35], but carcinogenesis occurs with
concurrent inactivation of the adenomatous polyposis coli (APC)
tumor suppressor gene [36]. Mutations in APC do not occur with
significant frequency in MM, and it remains unclear what specific
mutations cooperate with Ras in myeloma development. In on
going work, it will be important to determine the pathways that
cooperate with Ras activation to transform germinal center B-cells.
Methods
Mouse Strains
KrasG12D mice [13] (on C57BL/6 background) were crossed to
Cc1-Cre knock-in mice [17] (on C57BL/6 background) or AID-Cre-
YFP transgenic mice [18] (on 129/SvJ6C57BL/6 backgrounds)
to obtain double transgenic mice. Triple transgenic mice were
created by crossing KrasG12D mice to AID-Cre-YFP and Arf 2/2 or
Arf +/2 mice [20] (on 129/SvJ 6 C57BL/6 background)
(Figure 1). All mice were routinely observed up to 1 year after
birth in a specific pathogen-free facility.
Ethics Statement
This study was performed in strict accordance with animal use
protocols approved by the Washington University Institutional
Animal Care and Use Committee (IACUC, protocol number
20120152). Mice were euthanized if they met any early removal
Figure 6. Cutaneous papillomas in AID-Cre-YFP KrasG12D mice and acceleration of lethality by tumor-promoting treatments. A) Kaplan-
Meier survival curves of AID-Cre-YFP KrasG12D mice and control KrasG12D mice. Cohorts of AID-Cre-YFP KrasG12D and KrasG12D mice were subjected to
vitamin D deficient chow continuously from 8.5 weeks of age or a single dose of sub-lethal gamma irradiation or given both. All AID-Cre-YFP KrasG12D
mice developed progressive cutaneous papillomas that were made more extensive/aggressive with radiation or vitamin D deficiency. Mice were
sacrificed when morbidity developed, defined by weight loss, unkempt coat, hunched posture, and lethargy. Each AID-Cre-YFP KrasG12D group had
(n = 5) and developed papillomas, leading to infection, whereas every KrasG12D (n = 5) survived to day 352 endpoint. No B-cell phenotype was
observed in any cohort. B) Cre-mediated recombination of Kras locus in DNA from papillomas was detected by PCR in three separate papilloma
samples from AID-Cre-YFP KrasG12D mice. WT, wild-type control.
doi:10.1371/journal.pone.0067941.g006
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criteria (weight loss, lethargy, hunched posture, and/or ruffled
coat) to limit suffering, in accordance with NIH-approved
institutional animal care guidelines.
Kras Expression
Raw dataset files of Kras, Hras, and Nras expression in murine
B cells was accessible through www.ncbi.nlm.nih.gov/geo (acces-
sion GSE4142).
Stimulation of Germinal Centers
1 mg of (4-hydroxy-3-nitrophenyl) acetyl conjugated chicken
gamma globulin (NP-CGG; Biosearch Technologies, Novato,
California) was mixed with Freud’s Adjuvant, Complete (Sigma-
Aldrich, St. Louis, Missouri) for primary immunization or Freud’s
Adjuvant, Incomplete (Sigma-Aldrich) for boosting immunization
in 100 ul to inject intraperitoneally at specific time points (Figure
S5). Where indicated, AID-Cre-YFP KrasG12D mice were given a
Vitamin D deficient diet (Harlan, Madison, Wisconsin) beginning
at 8.5 weeks of age and/or 4 Gy of sub-lethal ionizing radiation at
12 weeks of age.
Molecular Genotyping of Mouse Strains
For genotyping by PCR, genomic DNA was extracted from tail
tissue using Extract-N-Amp Tissue Kit (Sigma-Aldrich). All primer
sequences used for genotyping are available upon request. To
detect Cre-mediated somatic recombination in bone marrow,
spleen, and tumors, genomic DNA was extracted using DNeasy
Blood and Tissue Kit (Qiagen, Germantown, Maryland), then
amplified using PCR to yield expected 622-bp WT and 650-bp
loxP, signifying recombination of the KrasG12D allele. Mature B cell
populations sorted from spleen and bone marrow DNA was
extracted using prepGEM Tissue Kit (ZyGEM, New Zealand).
Ex vivo Class Switch Recombination Assay
Splenocytes from 8–12 week old mice were purified by
immunomagnetic depletion of CD43 positive cells (Miltenyi,
Auburn, California). CD43 negative splenic naı¨ve B cells were
cultured with 15 ng/ml of IL-4 (R&D systems, Minneapolis,
Minnesota) and 20 ug/ml of LPS or LPS alone (Sigma-Aldrich) in
B cell medium (RPMI-1640 with L-Glutamine (Cellgro, Manassas,
Virginia), 1% HEPES, 1% penicillin/streptomycin/amphotericin
B, 10% FBS (Hyclone, South Logan, Utah)) at 8610ˆ5 cells/well of
a 6-well plate. Cells were removed from culture at days 0, 3, 5, and
7 for flow cytometric analysis and DNA extraction (Qiagen). On
day 5 and 7, cells were split and given 15 ng/ml of IL-4 and
20 ug/ml of LPS or LPS alone.
Histopathology
Mouse tissues were fixed in 10% neutral buffered formalin for at
least 48 hours, dehydrated in an alcohol gradient, cleared in
Figure 7. Aggressive papillomas and soft tissue sarcomas in AID-Cre-YFP KrasG12D Arf2/2mice. A) Gross appearance of progressive tumors
affecting an AID-Cre-YFP KrasG12D Arf 2/2 mouse at 13 weeks of age. Tumors progressed rapidly from smaller papillomas on the ventral neck. B)
Control AID-Cre-YFP Arf 2/2 control mouse at 13 weeks appears normal. Hematoxalin & eosin stains of C) spleen section from AID-Cre-YFP KrasG12D Arf
2/2 shows disruption of splenic architecture by inflammatory cells; D) spleen section from AID-Cre-YFP Arf 2/2 control appears normal; and E) section
of subcutaneous sarcoma from AID-Cre-YFP KrasG12D Arf 2/2 at 13 weeks shows spindle shaped cells consistent with soft tissue sarcoma. Original
magnification, x10 (spleen); x40 (sarcoma). Scale bar: 200 um (spleen); 50 um (sarcoma). Tumor development was uniform in AID-Cre-YFP KrasG12D Arf
2/2 mice and did not require any tumor-promoting treatment. Representative images are shown.
doi:10.1371/journal.pone.0067941.g007
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xylene, and infiltrated and embedded in paraffin. Sections were
stained for hematoxylin/eosin (H&E).
Flow Cytometric Analysis
Single cell suspensions of bone marrow and spleen briefly
underwent red blood cell lysis.
1610‘6 cells were pre-incubated for 3 minutes on ice with Fc
block (CD16/CD32; BD Pharmingen, Franklin Lakes, New
Jersey), stained for 25 min on ice with specific antibodies and
washed twice in PBS/0.5 M EDTA/0.5 g BSA. The following
antibodies used were obtained from BD Pharmingen, unless noted
otherwise: FITC-B220 (RA3-6B2), PE-IgM (II/41; eBioscience),
APC-IgG1 (X56), AlexaFluor-647 GL7 (eBioscience), PE-CD138
(281-2), PECy7-B220 (RA3-6B2), PE-CD4 (GK1.5), and FITC-
CD8. Flow cytometric analysis was performed using FACScan
(Becton Dickinson, Franklin Lakes, New Jersey), modified with
additional lasers (Cytek Development). FlowJo software (Tree Star,
Ashland, Oregon) was used to analyze a minimum of 10,000
events acquired during collection.
MoFlo
Two 8-week-old Cc1-Cre KrasG12D or Kras AID-Cre mice were
stimulated with 100 ug CGG intraperitoneally and sacrificed 14
days later. Preparation of spleen and bone marrow was previously
described. Flow cytometric analysis was performed with the MoFlo
single-cell sorter (Becton-Coulter, Brea, California).
ELISA and SPEP
Total IgA, IgM, IgG, IgG1, IgG2a, IgG2b, and IgG3 levels in
serum were measured by enzyme-linked immunosorbent assay
(ELISA, Bethyl Laboratories, Inc, Montgomery, TX). Serum
protein electrophoresis (SPEP) quantified albumin and globulin
proteins from serum using the spife3000 (Helena Laboratories,
Beaumont, Texas). Gels were scanned and analyzed using
Quickscan2000 software (Helena Laboratories).
Supporting Information
Figure S1 Flow cytometry of Cc1-Cre KrasG12D mouse
splenocytes undergoing class switch recombination ex
vivo. Cc1-Cre KrasG12D mouse splenocytes negatively selected for
CD43 and plated in media supplemented with LPS+IL-4. Flow
cytometry shows increase of B220+ IgM+ IgG1+ splenocytes at
day 3 with LPS+IL-4, compared to day 0.
(TIF)
Figure S2 Analysis of T-cell lymphomas and lung
tumors arising in Cc1-Cre KrasG12D mice. A) Flow
cytometry of single cell suspension of naı¨ve Cc1-Cre KrasG12D
mouse that developed fatal thymus tumor. Lymphoma cells appear
to be heterogeneous and composed of CD4+ and double positive
CD4/CD8 populations present in both tumor and spleen. Similar
results were obtained in 2 additional naı¨ve Cc1-Cre KrasG12D mice
that developed thymus tumors. B–E) Hematoxalin & eosin stains
of lung sections from immunized Cc1-Cre KrasG12D (B,C) and
control naı¨ve Cc1-Cre mice (D,E) showing incidentally discovered
lung tumors. Original magnification, x4 and x40. Scale bar:
500 um and 50 um. F) PCR of two lung nodule samples from 2
different Cc1-Cre KrasG12D mice show recombination of KrasG12D
locus.
(TIF)
Figure S3 Subtle changes in immunoglobulin isotype
responses in AID-Cre-YFP KrasG12D mice detected by
enzyme linked immunosorbant assay (ELISA). A) Total
serum gamma region protein levels from AID-Cre-YFP KrasG12D
and control KrasG12D mice calculated from total serum protein
multiplied by the percentage of protein in the gamma region of
serum protein electrophoresis (SPEP) divided by 100. Results are
shown from untreated AID-Cre-YFP KrasG12D vs KrasG12D mouse
cohorts (immunization protocol only; left panel), AID-Cre-YFP
KrasG12D vs KrasG12D cohorts fed vitamin D deficient chow (middle
panel) and AID-Cre-YFP KrasG12D vs KrasG12D cohorts given
radiation (right panel). B) Serum ELISA of indicated immuno-
globulin isotypes of untreated KrasG12D and AID-Cre-YFP KrasG12D
mice. All changes were small in magnitude, but statistically
significant differences were noted at baseline in IgM, IgA and
IgG3 isotypes, at 9 month IgG2b timepoint and total IgG at
endpoint. Serum samples were taken at baseline, prior to
immunization with NP-CGG; PPI, post-primary immunization;
PBI, post-boosting immunization; 9 mo, 9 month time point;
Endpt, endpoint prior to sacrifice. Student’s T-test, *, p,0.05, **,
p,0.01, *** p,0.001
(TIF)
Figure S4 AID-Cre-YFP KrasG12D Arf 2/2 shows minimal
changes in ELISA and serum protein electrophoresis
(SPEP). A) Total gamma region protein levels from serum of
AID-Cre-YFP KrasG12D Arf 2/2 (DKA, n = 3), AID-Cre-YFP KrasG12D
Arf +/2 (DKA+/2, n = 2), and control AID-Cre-YFP Arf 2/2 (DA,
n = 1) at baseline and 12 weeks, with no immunization. B) Serum
ELISA of IgM and IgG isotypes of AID-Cre-YFP KrasG12D Arf 2/2
(DKA, n = 3), AID-Cre-YFP KrasG12D Arf +/2 (DKA+/2, n = 2), and
control AID-Cre-YFP Arf 2/2 (DA, n = 1), with statistical
significance of IgM isotype of DKA and IgG isotype of DKA+/2.
Student’s T-test, *, p,0.05, **, p,0.01, *** p,0.001 C) SPEP gel
and representative graph showing a low gamma protein of control
AID-Cre-YFP Arf 2/2 at 12 weeks, compared to AID-Cre-YFP
KrasG12D Arf 2/2.
(TIF)
Figure S5 Protocol of immunization used in this study.
Mice were injected intraperitoneally with NP-CGG in Freund’s
complete adjuvant for primary immunization, followed 4 weeks
later by boosting immunization with NP-CGG in Freund’s
incomplete adjuvant (arrows). Serum was sampled (arrow heads)
at baseline prior to PI, four weeks after primary immunization
(post-primary immunization; PPI), four weeks after boosting
immunization (post-boosting immunization; PBI), at nine months
and prior to sacrifice.
(TIF)
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